Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have a blood cancer or lymphoma that involves a protein called CD22, and your cancer has come back or stopped responding to treatment after trying at least 2 different standard treatments (including a CD19-targeted therapy, if your cancer has CD19)
- Your cancer either came back a second time after standard relapse treatment (including CD19 CAR T-cell therapy), or it never went into remission after 2 rounds of chemotherapy
- You are between 1 and 80 years old
- Lab tests show that CD22 is present on at least 70% of your cancer cells
- Your blood has enough of a certain type of immune cell called CD3 (above a specific level measured by a blood test)
- You are well enough to carry out some daily activities, measured by a standard health scale (called Karnofsky if you are over 10 years old, or Lansky if you are 10 or younger) — with exceptions if certain symptoms like weakness are caused directly by the cancer
- If you are able to become pregnant, you must have a negative pregnancy test
- Your heart is pumping well enough, as confirmed by a heart scan
- It has been at least 60 days since a bone marrow transplant (if you have had one)
- It has been at least 30 days since a previous CAR T-cell therapy (if it did not work for you)
Who may not be able to join:
- (No exclusion criteria were listed in the provided information — confirm with the trial site for any restrictions that may apply)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Prof. Elad Jacoby, MD, Sheba Medical Center
Phone: 972 03 5309046
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety Evaluation: Treatment Related Toxicities; Efficacy Evaluation; Minimal toxic dose evaluation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.